Axon Enterprise, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Has Buying Axon Stock's Dips Paid Off? - trefis.com

Earnings report Financial outlook AI-generated analysis

📉 AXON shares declined 16.6% between September 22 and October 19, 2026, with a sharp 6.4% drop on October 16.

📈 Historical data shows that 14 out of 19 prior annualized drops left the stock trading higher twelve months later, with a median gain of 58%.

💰 Axon generated $904 million in revenue for fiscal Q2 2026, marking a 35.3% increase from a year earlier.

🚀 Management credited products such as Dedrone, TASER 10, and Axon Body 4 for the rise in device sales.

📊 The company raised the midpoint of its fiscal 2026 revenue growth forecast to 33%, up from 31% in May.

⚠️ Axon recorded an operating margin of 0.7% over the twelve months ending June 30, 2026, compared with 18.5% for the S&P 500.

📉 The stock trades at 9.6 times sales, significantly higher than the 3.1 times multiple for the S&P 500.

🏭 Axon reported negative free cash flow in fiscal Q1 and Q2 2026, resulting in a combined outflow of about $56 million.

📦 Management stated the company is making substantial inventory investments to support customer demand and reduce supply chain risk.

💾 Rising component costs, especially for memory, are cited as a factor impacting cash flow dynamics.

🔮 Axon expects spending on inventory investments to moderate after 2026.

💵 Management projects about $450 million of free cash flow for the full fiscal year 2026.

👀 Investors should watch Axon's free cash flow for fiscal Q3 2026 in the next report.

📊 Over five years to October 2026, VSE stock rose 239% while Axon Enterprise stock rose 107%.

Bullish Signals
  • Axon generated $904 million in revenue for fiscal Q2 2026, marking a 35.3% increase from a year earlier.
  • This represents the company's 10th straight quarter of growth above 30%, demonstrating consistent top-line expansion.
  • Management raised the midpoint of the fiscal 2026 revenue growth forecast to 33%, up from 31% in May.
  • Device sales are being driven by successful products such as Dedrone, TASER 10, and Axon Body 4.
  • The stock trades at 9.6 times sales, reflecting a market bet that current growth will eventually convert into higher profitability.
Risk Factors
  • Profitability has not matched the sales pace, with an operating margin of 0.7% compared to 18.5% for the S&P 500.
  • The company reported negative free cash flow in both fiscal Q1 and Q2 2026, resulting in a combined outflow of about $56 million.
  • Management cited rising component costs, especially for memory, as a driver of the negative cash flow situation.
  • Buyers who entered during previous drops often had to sit through further falls before the stock reached its best price for the year.
Full Analysis
AXON Enterprise (AXON) shares experienced a significant decline of 16.6% between the close on September 22 and October 19, 2026, with the sharpest single-day loss occurring on October 16. Historical analysis indicates that out of 19 prior drops with a full year behind them, 14 resulted in higher stock prices twelve months later, though buyers typically endured further declines before recovery. Financially, Axon reported $904 million in revenue for fiscal Q2 2026, representing a 35.3% increase from the prior year and marking the tenth consecutive quarter of growth exceeding 30%. Management attributes this surge to device sales driven by products like Dedrone, TASER 10, and Axon Body 4, subsequently raising the midpoint of its fiscal 2026 revenue growth forecast to 33%. Despite robust top-line expansion, profitability lags significantly behind peers; Axon recorded an operating margin of just 0.7% over the twelve months ending June 30, 2026, compared to 18.5% for the S&P 500. The company also reported negative free cash flow in the first half of fiscal 2026 due to substantial inventory investments aimed at supporting demand and mitigating supply chain risks, particularly regarding rising memory component costs. Management expects inventory spending to moderate after 2026 and projects approximately $450 million in full-year free cash flow, requiring strong performance in the second half. Investors are currently betting that Axon can successfully convert its rapid sales growth into sustainable profitability once inventory levels stabilize.